M. Sionidou

Adherence to inhaled therapies over 4 years in people with cystic fibrosis

E. Papadaki, E. Hatziagorou, J. Tsanakas, 2022, Pediatric pulmonology.

Severe Pulmonary Disease Caused by Mycolicibacter kumamotonensis

F. Kontos, I. Kioumis, Dimitrios Papaventsis, 2021, Emerging infectious diseases.

Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections.

M. Papaioannou, I. Kioumis, G. Pitsiou, 2013, International journal of antimicrobial agents.

Tuberculosis treatment outcome in Thessaloniki, Greece - a single center study.

I. Kioumis, T. Kontakiotis, E. Papadaki, 2019, Hippokratia.

Moxifloxacin in Chronic Obstructive Pulmonary Disease: Pharmacokinetics and Penetration into Bronchial Secretions in Ward and Intensive Care Unit Patients

P. Zarogoulidis, I. Kioumis, G. Pitsiou, 2019, Antimicrobial Agents and Chemotherapy.

Is daily exposure to ozone associated with respiratory morbidity and lung function in a representative sample of schoolchildren? Results from a panel study in Greece

E. Samoli, K. Dimakopoulou, K. Katsouyanni, 2017, Journal of Exposure Science and Environmental Epidemiology.

Hepatocellular carcinoma (HCC) in a patient with cystic fibrosis and liver disease (cirrhosis)

K. Vasileiou, I. Kioumis, K. Manika, 2022, Pneumon.

Treatment for tuberculosis due to sensitive strains: To shorten or not to shorten?

A. Loukeri, K. Manika, M. Sionidou, 2023, Pneumon.

Interferon α–induced sarcoidosis to a patient with polycythemia vera

L. Sichletidis, M. Sionidou, D. Spyratos, 2011, BMJ Case Reports.